Lenalidomide in International Prognostic Scoring System Low and Intermediate-1 risk myelodysplastic syndromes with del(5q): an Italian phase II trial of health-related quality of life, safety and efficacy

2013 ◽  
Vol 54 (11) ◽  
pp. 2458-2465 ◽  
Author(s):  
Esther N. Oliva ◽  
Roberto Latagliata ◽  
Carmelo Laganà ◽  
Massimo Breccia ◽  
Sara Galimberti ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Myelodysplastic Syndromes ◽  
Scoring System ◽  
Phase Ii Trial ◽  
International Prognostic Scoring System ◽  
Health Related Quality ◽  
Safety And Efficacy ◽  
Related Quality ◽  
Health Related

Health-related-quality-of-life and toxicity after single fraction 19 Gy high-dose-rate prostate brachytherapy: Phase II trial

2018 ◽  
Vol 126 (2) ◽  
pp. 278-282 ◽  
Author(s):  
Alfonso Gomez-Iturriaga ◽  
Francisco Casquero ◽  
Jose Ignacio Pijoan ◽  
Pablo Minguez ◽  
Jose Maria Espinosa ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Dose Rate ◽  
Phase Ii Trial ◽  
High Dose Rate ◽  
High Dose ◽  
Prostate Brachytherapy ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

scholarly journals The Effect of Lenalidomide on Health-Related Quality of Life in Patients With Lower-Risk Non-del(5q) Myelodysplastic Syndromes: Results From the MDS-005 Study

2018 ◽  
Vol 18 (2) ◽  
pp. 136-144.e7 ◽  
Author(s):  
Valeria Santini ◽  
Antonio Almeida ◽  
Aristoteles Giagounidis ◽  
Uwe Platzbecker ◽  
Rena Buckstein ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Myelodysplastic Syndromes ◽  
Lower Risk ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

scholarly journals Targeting health-related quality of life in patients with myelodysplastic syndromes – Current knowledge and lessons to be learned

Blood Reviews ◽  
2021 ◽  
pp. 100851
Author(s):  
Esther N. Oliva ◽  
Uwe Platzbecker ◽  
Pierre Fenaux ◽  
Guillermo Garcia-Manero ◽  
Thomas W. LeBlanc ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Myelodysplastic Syndromes ◽  
Current Knowledge ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

scholarly journals The anemia-independent impact of myelodysplastic syndromes on health-related quality of life

2021 ◽  
Author(s):  
Hanneke J. C. M. Wouters ◽  
Annette Conrads-Frank ◽  
Karin A. Koinig ◽  
Alex Smith ◽  
Ge Yu ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Regression Analysis ◽  
Myelodysplastic Syndromes ◽  
Lower Risk ◽  
Large Population ◽  
Index Score ◽  
Health Related Quality ◽  
Related Quality ◽  
Health Related

AbstractMyelodysplastic syndromes (MDS) are in the majority of cases characterized by anemia. Both anemia and MDS per se may directly contribute to impairments in health-related quality of life (HRQoL). In this study, we aimed to investigate the anemia-independent impact of MDS on HRQoL. We evaluated participants (≥ 50 years) from the large population-based Lifelines cohort (N = 44,694, mean age 59.0 ± 7.4 years, 43.6% male) and the European MDS Registry (EUMDS) (N = 1538, mean age 73.4 ± 9.0 years, 63.0% male), which comprises a cohort of lower-risk MDS patients. To enable comparison concerning HRQoL, SF-36 scores measured in Lifelines were converted to EQ-5D-3L index (range 0–1) and dimension scores. Lower-risk MDS patients had significantly lower HRQoL than those from the Lifelines cohort, as illustrated in both the index score and in the five different dimensions. Multivariable linear regression analysis demonstrated that MDS had an adjusted total impact on the EQ-5D index score (B =  − 0.12, p < 0.001) and an anemia-independent “direct” impact (B =  − 0.10, p < 0.001). Multivariable logistic regression analysis revealed an anemia-independent impact of MDS in the dimension mobility, self-care, usual activities, and anxiety/depression (all except pain/discomfort). This study demonstrates that the major part of the negative impact of lower-risk MDS on HRQoL is not mediated via anemia. Thus, the therapeutic focus should include treatment strategies directed at underlying pathogenic mechanisms to improve HRQoL, rather than aiming predominantly at increasing hemoglobin levels.

Health-Related Quality of Life Profile and Request of Prognostic Information on Survival At the Time of Diagnosis in Patients with High-Risk Myelodysplastic Syndromes

Blood ◽  
2011 ◽  
Vol 118 (21) ◽  
pp. 2078-2078
Author(s):  
Fabio Efficace ◽  
Gianluca Gaidano ◽  
Reinhard Stauder ◽  
Giovanni Caocci ◽  
Maria Teresa Voso ◽  
...  
Keyword(s):  
Quality Of Life ◽  
High Risk ◽  
Myelodysplastic Syndromes ◽  
Health Related Quality ◽  
Prognostic Information ◽  
Related Quality ◽  
Eortc Qlq C30 ◽  
Health Related ◽  
Eortc Qlq

Abstract Abstract 2078 Background: Health-related quality of life profile (HRQOL) of patients diagnosed with high-risk myelodysplastic syndromes (MDS) can be compromised already at the time of diagnosis before receiving any kind of treatment. Clinical decision-making is challenging due to the poor prognosis and no data exist on the possible relationships between patient's HRQOL and the request of prognostic information on survival during consultation. Aim: The main objectives were to assess preferences for prognostic information of patients with high-risk MDS and the relationship between such preferences and patient characteristics including HRQOL. To date no such evidence exists in this population. Patients and Methods: Data were gathered through an ongoing international prospective observational study that recruits newly diagnosed patients with MDS. These patients typically have a limited life expectancy. At the time of diagnosis, and during one of the first clinical consultations in which treatment options were discussed, patients completed the European Organization for Research and treatment of Cancer, Quality of life Questionnaire (EORTC QLQ-C30). The EORTC QLQ-C30 is a psychometrically robust generic HRQOL cancer measure assessing both symptoms and functional aspects. Physicians also completed an extensive survey about their patient's preference for involvement in treatment decisions and whether the patient explicitly requested prognostic information for survival. Associations between request for prognostic information, HRQOL socio-demographic characteristics (i.e., living arrangements, age, gender, education) and clinical data including: performance status, comorbidity and disease severity (i.e. IPSS risk category intermediate 2 vs. high risk) were investigated using Fisher's exact test and Wilcoxon-Mann-Whitney test as appropriate. Results: Overall, 184 patients (36% female and 64% male) were analyzed. Mean age of patients was 70 years (range: 31–88). 65% explicitly requested information about expected survival at the time of diagnosis. The symptom profile of patients requesting prognostic information was better than those who did not in 7 out of the 8 symptoms evaluated. The largest clinically meaningful difference was found for fatigue with a mean score of 39 (SD:26) and 52 (SD:28) respectively for those requesting prognostic information versus those who did not. Request for prognostic information was significantly associated with younger age (P=.01) and fewer comorbidities (P=.04). In addition, better physical functioning (P=.009), better role functioning (P=.002) and a lower level of fatigue (P=.002) were also associated with a request for prognostic information during consultation. Additional supportive analysis revealed that patients with a higher overall mean symptom score did not request information about survival (P=.02). Conclusion: These data suggest that the majority of patients with high-risk MDS request prognostic information on survival from their physicians at the time of diagnosis. There is also an indication that patients who are more likely to request such information are those who are in better health condition reporting higher functional abilities and lower symptoms. Disclosures: No relevant conflicts of interest to declare.

Sign in / Sign up

Export Citation Format

Share Document